0001104659-25-101914.txt : 20251024 0001104659-25-101914.hdr.sgml : 20251024 20251023202751 ACCESSION NUMBER: 0001104659-25-101914 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251024 DATE AS OF CHANGE: 20251023 EFFECTIVENESS DATE: 20251024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Theriva Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-561937 FILM NUMBER: 251414081 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Synthetic Biologics, Inc. DATE OF NAME CHANGE: 20120305 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 D 1 primary_doc.xml X0708 D LIVE 0000894158 Theriva Biologics, Inc. 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD MARYLAND 20850 301-417-4364 NEVADA SYNTHETIC BIOLOGICS, INC. Synthetic Biologics, Inc. ADEONA PHARMACEUTICALS, INC. PIPEX PHARMACEUTICALS, INC. Corporation true Steven A. Shallcross 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Executive Officer Director Jeffrey J. Kraws 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director John Monahan 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director Jeffrey A. Wolf 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director Biotechnology Decline to Disclose 06b false 2025-10-17 false true true false 0 A.G.P./Alliance Global Partners 000008361 None None 590 MADISON AVENUE 36th Floor New York NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NY NEW YORK true 13109494 13109494 0 Includes $4,369,831.20 in proceeds from exercise of existing registered warrants pursuant to Warrant Inducement Letter Agreement and $8,739,663 in total gross proceeds to be received from cash exercise of all new warrants issued in private placement. false 10 308000 true 0 A.G.P/Alliance Global Partners LP was paid by the Issuer a cash fee equal to 7.0% of the aggregate gross proceeds received upon exercise of the existing registered warrants and reimbursement of certain expenses. 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers false Theriva Biologics, Inc. /s/ Steven A. Shallcross Steven A. Shallcross Chief Executive Officer and Chief Financial Officer 2025-10-23